Table 1.
Details of the study subjects
| Groups | N | Gender male/female | Ages (mean ± SD) | HBeAg (+) | Anti-HBe (+) | Anti-HBc (+) | ALT (>40 IU/mL) | AFP (>20 ng/mL) | Viral loads, geometric mean (IU/mL) (min-max) |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Anti-HBe (+) | HBeAg (+) | |||||||||
| Healthy controls | 50 | 35/15 | 44.0±11.6 | |||||||
| HBsAg (−) patients with other cancers | 39 | 14/25 | 46.9±10.8 | |||||||
| HBsAg (−) patients with HCC or LC | 12Δ | 7/5 | 51.2±15.9 | 3 | 7 | |||||
| Asymptomatic HBsAg carriers | 62 | 45/17 | 49.5±6.6 | 12 | 43 | 59 | 3 | 0 | 3.75 (1.48–7.82) | 6.12 (2.73–8.16) |
| HBsAg (+) chronic liver disease patients* | 28 | 25/3 | 41.4±10.8 | 10 | 15 | 29 | 17 | 8 | 3.77 (2.69–7.20) | 4.73 (2.70–7.99) |
| HBsAg (+) HCC# patients | 50 | 40/10 | 50.4±9.4 | 6 | 37 | 49 | 29 | 34 | 3.55 (1.47–7.14) | 5.34 (2.70–7.40) |
| Total | 241 | 166/75 | 47.3±10.5 | 28 | 95 | 137 | 52 | 49 | 3.68 (1.48–7.82) | 5.40 (2.70–8.16) |
AFP, alpha-fetoprotein; ALT, alanine aminotransferase.
*
These patients include chronic hepatitis and LC.
#
HCC, hepatocellular carcinoma; LC, liver cirrhosis.
Δ
7 HCC and 5 LC.